格隆汇2月9日丨光库科技(300620.SZ)涨17.91%，报185.000元，股价创历史新高，总市值460.98亿元。 ...

长江商报消息 ●长江商报记者 李璟 业绩显著增长，东田微（301183.SZ）加大产业布局。 2月6日晚，东田微发布公告，公司计划在东莞市道滘镇昌平村投资建设"东田微全球研发中心及华南制 造总部项目"，项目投资总额为4亿元。 从研发投入来看，2022年至2024年，东田微的研发费用分别为2629万元、3275万元、3806万元，自上市 以来不断增长。2025年前三季度，公司研发费用为3475万元，研发费率接近6%。 对于本次投资，东田微表示，此项目的建设将有利于建立现代化产业研集群，促进公司中长期战略规划 落地，提高公司综合竞争力，更好满足客户就近配套的需求。 受AI算力需求持续攀升驱动，2025年东田微数通市场高速光模块需求显著增长，带动公司高速光模块 WDM滤光片、光隔离器等通信类光学元器件销售收入快速提升。 根据东田微此前发布的业绩预告，预计公司2025年度归母净利润为9600万元到11000万元，同比增长 71.98%到97.06%。 华南投建项目加大产业布局 公开资料显示，东田微成立于2009年，于2022年5月上市，是湖北宜昌当阳的一家专业从事精密光电薄 膜元件研发、生产和销售的国家级高新技术企业 ...

记者丨杨韵琪 编辑丨梁明 过去一周（2月2日—2月6日），A股三大指数集体收跌。截至2月6日收盘，沪指周跌1.27%，深 成指周跌2.11%，创业板指周跌3.28%。 近44%的个股周内实现上涨，光伏设备、钙钛矿电池、赛马概念、TOPCON电池等板块涨幅居 前，贵金属、金属铅、转基因等板块跌幅居前。 沾A I就火，最牛股收获2 0 c m四连板 图源：Wind 2月5日，民爆光电公布股票交易 异常波动及股票交易严重异常波动公告。 民爆光电在公告中表示，公司股票在2026年2月4日和2月5日连续两个交易日内收盘价涨幅累计偏 离45.76%，构成股票交易异常波动；在2026年2月2日至2月5日连续四个交易日内涨幅 累计偏离 109.05% ，属于严重异常波动。 公司目前经营正常，公司经营情况及内外部经营环境未发生重大变化。公司收购厦芝精密的审计 评估尚在进行中。本次交易仍需公司再次召开董事会审议，且发行股份购买资产事宜后续还需股 东大会批准，并上报深交所审核、证监会注册，最终能否成功实施存在不确定性。 剔除最近一个月上市的次新股，本期牛股榜中， 民爆光电（301362.SZ）以115.92%的周涨幅夺 魁， 凯龙 ...

Core Viewpoint - Qingyue Technology (688496) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which may lead to significant legal consequences including potential delisting [1][3] Company Announcements Summary - Qingyue Technology received a notice from the CSRC on November 1, 2025, regarding the investigation for suspected false financial reporting, and the investigation is still ongoing with no conclusive opinions or decisions received yet [1][3] - The company has been actively cooperating with the investigation and is required to disclose risk announcements monthly, with designated media for information disclosure being the Shanghai Stock Exchange website and several financial newspapers [1] - As a result of the investigation, three securities accounts holding a total of 1,631,343 shares (all repurchased shares) and seven bank accounts with a total of 133,644,123.04 yuan in frozen funds (all related to fundraising) have been frozen [1][3]

Group 1 - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties, aimed at treating advanced or metastatic pancreatic cancer with KRAS G12D mutation in combination with gemcitabine and albumin-bound paclitaxel, with a total R&D investment of approximately 254 million yuan [1] - Fenglong Co. announced a significant stock price increase of 491.97% from December 25, 2025, to February 5, 2026, and may apply for a trading suspension if prices continue to rise abnormally [2] - Aier Eye Hospital clarified that the reported Xiangyang Hengtai Kang is not affiliated with the company, but is a joint venture established by Aier Medical Investment Group and other investors [3] Group 2 - XWANDA's subsidiary reached a settlement with Weir Electric, which is expected to impact the company's net profit attributable to shareholders by 500 million to 800 million yuan in 2025 [4] - Tianzhong Precision Machine received a lawsuit from eight creditors of its former subsidiary, involving a claim of 108 million yuan [5] - Dongtian Micro plans to invest 400 million yuan to establish a global R&D center and manufacturing headquarters in Dongguan, focusing on precision optical components for optical communication [6] Group 3 - Lvtong Technology's industrial fund plans to invest 10 million yuan in Shenghao Optoelectronics, which specializes in testing equipment for optical communication chips [7] - Tiansheng New Materials has been investigated by the China Securities Regulatory Commission for suspected violations of information disclosure laws [8] - Yahui Long has been placed under investigation by the CSRC for suspected information disclosure violations [9] Group 4 - Longyun Co. plans to acquire 58% of Yuheng Film Industry through a share issuance, with the target company's valuation estimated between 450 million and 530 million yuan [10] - Hu Silicon Industry announced that the National Integrated Circuit Industry Investment Fund plans to reduce its stake by up to 3% [11] - Perfect World reported that its actual controller has reduced his stake by 1.70% through various transactions [12] Group 5 - Sanfu Co. announced that its shareholder, Tangshan Yuanheng Technology Co., intends to reduce its stake by up to 3% [13] - Wanshan Expressway plans to invest 5.42 billion yuan in the expansion of the G30 Lianhuo Expressway in Anhui [14] - New Hope reported sales of 1.1218 million pigs in January, generating revenue of 1.628 billion yuan [15]

证券日报网讯2月6日，福晶科技（002222）在互动平台回答投资者提问时表示，公司根据业务布局和经 营计划有序推进研发项目，具体经营信息以公司定期报告或临时公告披露的信息为准。 ...

Core Viewpoint - The polarized film sector experienced a significant surge, with multiple companies reaching their daily price limit, indicating strong market interest and potential investment opportunities [1]. Group 1: Market Performance - The polarized film sector saw substantial gains, with companies such as Shanshan Co., Ltd. and Bole Technology hitting the daily limit up [1]. - Anhui Wuwei High-tech also reached the daily limit up, reflecting a broader positive trend in the sector [1]. - Yitian Co., Ltd. and other stocks in the sector showed notable increases, contributing to the overall market performance [1].

2、公司于2026年1月27日至2026年2月5日在公司内部公示栏对本次拟激励对象的姓名和职务进行了公 示，公示期共计10天，公司员工可向公司董事会薪酬与考核委员会提出意见。截至公示期满，公司董事 会薪酬与考核委员会未收到任何组织或个人对本次拟激励对象提出的异议。 3、薪酬与考核委员会对激励对象的核查方式 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688127 证券简称：蓝特光学 公告编号：2026-015 浙江蓝特光学股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票 激励计划激励对象名单的公示情况说明及核查意见 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 浙江蓝特光学股份有限公司（以下简称"公司"）于2026年1月26日召开第五届董事会第二十六次会议， 审议通过了《关于公司〈2026年限制性股票激励计划（草案）〉及其摘要的议案》等议案。根据《上市 公司股权激励管理办法》（以下简称"《管理办法》"）《上海证券交易所科创板股票上市规则》《科创 板上市公司自律监管指南第4号一一股权激励信息披 ...

智通财经APP讯，奥比中光(688322.SH)发布公告，公司于2026年2月5日收到上海证券交易所出具的 《关于奥比中光科技集团股份有限公司向特定对象发行股票的交易所审核意见》，具体意见如下："奥 比中光科技集团股份有限公司向特定对象发行股票申请符合发行条件、上市条件和信息披露要求。本所 将在收到你公司申请文件后提交中国证监会注册。" ...

机构评级详情见下表： 国元国际发布研报称，预测丘钛科技(01478.HK)2025~2027年收入分别为198.04（+22.6%）、219.53 （+10.9%）和244.77（+11.5%）亿元人民币，归母净利润14.26（+411%）、9.1（-36.2%）和10.92 （+17.8%）亿元人民币。按照稳健原则，该行认为按照2026年15倍PE估值是合理的，对应目标价12.89 港元/股，距离现价有37.2%的上升空间，给予"买入"评级。 投行对该股的评级以买入为主，近90天内共有3家投行给出买入评级，近90天的目标均价为13.26港元。 国元国际控股最新一份研报给予丘钛科技买入评级，目标价12.89港元。 丘钛科技港股市值111.82亿港元，在光学光电子行业中排名第2。主要指标见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...